Mesoblast Ltd (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.91 billion
P/E Ratio 0.14
Dividend Yield 0.00%
Shares Outstanding 1.14 billion
Earnings per share -0.089
Dividend per share N/A
Year To Date Return 716.13%
Earnings Yield 711.28%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Mesoblast Ltd (ASX: MSB)
    Latest News

    Red arrow going down and symbolising a falling share price.
    Technology Shares

    Why has the Mesoblast share price crashed 40% since April?

    The tech share extends losses today.

    Read more »

    A young man wearing a black and white striped t-shirt looks surprised.
    Earnings Results

    Mesoblast share price spikes amid 'substantial reduction in operational spend'

    Mesoblast also completed the resubmission of its Biologics License Application (BLA) for remestemcel-L to the FDA last quarter.

    Read more »

    An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
    Healthcare Shares

    Mesoblast share price dips amid latest class action news

    The company is being taken to court by another unhappy shareholder.

    Read more »

    most shorted shares webjet
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    The words short selling in red against a black background
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    most shorted ASX shares
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    Green arrow going up on stock market chart, symbolising a rising share price.
    Share Gainers

    Why Brickworks, JB Hi-Fi, Mesoblast, and Sayona shares are charging higher

    These ASX shares are on form on Thursday...

    Read more »

    high, climbing, record high
    Healthcare Shares

    Here's why the Mesoblast (ASX:MSB) share price is climbing today

    Investors appear pleased.

    Read more »

    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    most shorted shares webjet
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    Rocket powering up and symbolising a rising share price.
    Share Gainers

    These were the best performing ASX 200 shares last week

    These ASX 200 shares were on form last week...

    Read more »

    A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
    Share Market News

    ASX 200 (ASX:XJO) midday update: Block falls, Nickel Mines jumps

    Here's what is happening on the ASX 200 today...

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Ltd

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    MSB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 Dec 2024 $2.55 $0.02 0.79% 7,505,632 $2.62 $2.70 $2.55
    23 Dec 2024 $2.53 $0.11 4.55% 13,221,879 $2.41 $2.67 $2.41
    20 Dec 2024 $2.42 $-0.63 -20.66% 34,450,998 $2.65 $2.75 $2.37
    19 Dec 2024 $3.05 $1.07 54.04% 46,747,972 $2.36 $3.09 $2.35
    18 Dec 2024 $1.98 $0.04 2.06% 6,967,092 $1.94 $2.03 $1.94
    17 Dec 2024 $1.94 $0.11 6.01% 7,999,348 $1.88 $1.96 $1.84
    16 Dec 2024 $1.83 $-0.01 -0.54% 6,269,896 $1.80 $1.90 $1.80
    13 Dec 2024 $1.84 $0.23 14.24% 14,026,481 $1.61 $1.87 $1.57
    12 Dec 2024 $1.62 $-0.01 -0.61% 6,150,830 $1.60 $1.65 $1.55
    11 Dec 2024 $1.63 $-0.07 -4.12% 6,339,118 $1.71 $1.77 $1.63
    10 Dec 2024 $1.70 $0.04 2.42% 6,644,655 $1.70 $1.75 $1.69
    09 Dec 2024 $1.66 $0.00 0.00% 5,906,394 $1.69 $1.74 $1.65
    06 Dec 2024 $1.66 $-0.01 -0.60% 6,355,849 $1.66 $1.72 $1.66
    05 Dec 2024 $1.67 $-0.09 -5.11% 16,478,648 $1.88 $1.88 $1.57
    04 Dec 2024 $1.76 $-0.09 -4.86% 5,327,581 $1.84 $1.85 $1.75
    03 Dec 2024 $1.85 $0.05 2.78% 9,045,086 $1.81 $1.87 $1.73
    02 Dec 2024 $1.80 $0.03 1.69% 4,692,824 $1.79 $1.82 $1.77
    29 Nov 2024 $1.77 $0.03 1.72% 2,353,723 $1.75 $1.79 $1.73
    28 Nov 2024 $1.74 $-0.02 -1.14% 4,655,494 $1.78 $1.82 $1.74
    27 Nov 2024 $1.76 $0.05 2.93% 4,497,278 $1.70 $1.79 $1.69
    26 Nov 2024 $1.71 $0.03 1.79% 5,206,356 $1.74 $1.75 $1.64

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    09 Jul 2024 Philip Krause Issued 985,000 $1,078,575
    Issue of options.
    08 May 2024 Eric Rose Buy 19,734 $151,207
    On-market trade. US$
    30 Apr 2024 Eric Rose Buy 21,428 $142,318
    On-market trade. US$ ADS
    12 Apr 2024 Jane Bell Buy 233,918 $199,999
    On-market trade.
    10 Jan 2024 Joseph Swedish Issued 827,077 $235,716
    Issue of options.
    10 Jan 2024 Philip Facchina Issued 290,432 $82,773
    Issue of options.
    10 Jan 2024 Jane Bell Issued 326,729 $93,117
    Issue of options.
    10 Jan 2024 William (Bill) Burns Issued 409,651 $116,750
    Issue of options.
    10 Jan 2024 Silviu Itescu Issued 3,693,070 $1,052,524
    Issue of options.
    10 Jan 2024 Eric Rose Issued 1,960,765 $558,818
    Issue of options.
    29 Dec 2023 Joseph Swedish Buy 850 $917
    On-market trade. US$
    28 Dec 2023 Philip Krause Buy 37,500 $41,536
    On-market trade. US$
    28 Dec 2023 Joseph Swedish Buy 91,035 $99,082
    On-market trade. US$
    28 Dec 2023 William (Bill) Burns Issued 21,250 $6,375
    Rights issue.
    28 Dec 2023 Jane Bell Issued 61,905 $18,571
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Silviu Itescu Chief Executive OfficerExecutive Director Jun 2004
    Dr. Itescu, prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. Itescu has consulted for international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies.
    Dr Eric A Rose Non-Executive Director Apr 2013
    Dr. Rose is a physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion. Former directorships of listed public companies within the last 3 years: Chairman, SIGA Technologies, Inc. (2017 - 2021), Non-executive Director, ABIOMED, Inc. which was acquired by Johnson & Johnson. (2007 - 2012, 2014 - 2022
    Mr William (Bill) A Burns Non-Executive DirectorVice-Chairman Mar 2014
    Mr. Burns spent his entire management career at the Beecham Group and F. Hoffmann-La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/ Bonn in Germany. In 2014, he was appointed a trustee of the Institute of Cancer Research(ICR), London, and in 2016 a Governor of The Wellcome Trust in London, UK. Mr Burns completed his terms of office at both ICR and Wellcome Trust and has retired from both positions.
    Ms Jane Catherine Bell Non-Executive Director Aug 2022
    Ms. Bell AM has 30 years of experience as a banking and finance lawyer with law firms, financial services and corporate treasury operations in the United States, Canada, Australia and the United Kingdom. She is an experienced Chair and non-executive Director in regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. Ms. Bell currently serves as Deputy Chair of Monash Health, Australia's public health service delivering more than 3.46 million episodes of care, and Chair of its Audit Committee. She is also a director of publicly-listed biotechnology company Amplia Therapeutics and Chair of its Audit Committee and of Jessie McPherson Private Hospital. She is a former Chair of Royal Melbourne Hospital and former Chair of Biomedical Research Victoria as well as of Advisory Groups for the Royal Australian and New Zealand College of Obstetricians and Melbourne Genomics Health Alliance, a former director of Hudson Institute of Medical Research and Chair of its Intellectual Property and Commercialization Committee and director of U Ethical, Australia's first ethical funds manager. Other current directorships of listed public companies: Non-Executive Director, Amplia Therapeutics Limited (since 2021). She is member of Risk Committee.
    Mr Philip J. Facchina Non-Executive Director Mar 2021
    Mr. Facchina brings more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter, overseeing the company's strategic relationships, including its relationships with the broad US ambulatory surgical center (ASC) market and its constituents. Prior to SurgCenter, Mr. Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. From 2008 to 2017, Mr. Facchina served as a Partner, Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset Management, an institutional investment management firm, and from 1998 to 2008 Mr. Facchina led the technology, media, and communications and healthcare investment banking groups of FBR Capital Markets. Mr. Facchina currently serves as an independent director for ViON Corporation and MilltechFX, and is Advisor to the CEO of Johanna Foods Inc, where he chairs the Audit Committee. Previously, among other directorships and committee posts, Mr. Facchina served on the Board of Web.com (Nasdaq: WEB), where he led Corporate Governance. He is member of Risk Committee.
    Dr Philip R Krause Non-Executive Director Mar 2022
    Dr Krause, with over 30 years of experience at the Food and Drug Administration, Dr. Krause has a combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. He recently served as deputy director of FDA's Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US from 2011-2021. Dr Krause has a strategic advisory consulting role with Mesoblast, providing advice on regulatory strategies.
    Ms Niva Sivakumar Joint Company Secretary Oct 2019
    -
    Mr Paul Hughes Joint Company Secretary Apr 2022
    -
    Andrew Chaponnel, Chief Financial Officer
    -
    Peter Howard Group General Counsel and Corporate Executive
    -
    Justin Horst Head of Manufacturing
    -
    Geraldine Storton Head of Regulatory Affairs and Quality Management
    -
    Niva Sivakumar Joint Company Secretary
    -
    Paul Hughes Joint Company Secretary
    -
    Michael Schuster Pharma Partnering
    -
    Paul Simmons Scientific Advisor to the Chief Executive Officer
    -
    Fiona Se SVP and Head Translational Research
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 372,563,409 32.63%
    HSBC Custody Nominees (Australia) Limited 127,511,937 11.17%
    Citicorp Nominees Pty Limited 73,041,006 6.40%
    Professor Silviu Itescu 67,751,838 5.93%
    UBS Nominees Pty Ltd 14,630,688 1.28%
    Thorney Holdings Pty Ltd 10,000,000 0.88%
    Tiga Trading Pty Ltd 10,000,000 0.88%
    BNP Paribas Noms Pty Ltd 9,515,494 0.83%
    Josaka Investments Pty Ltd 8,821,137 0.77%
    Independent Asset Management Pty Limited 6,715,891 0.59%
    Merrill Lynch (Australia) Nominees Pty Limited 5,684,853 0.50%
    HSBC Custody Nominees (Australia) Limited i 5,301,000 0.46%
    BNP Paribas Nominees Pty Ltd 5,011,552 0.44%
    BNP Paribas Nominees Pty Ltd i 4,086,170 0.36%
    Mr Gregory John Matthews & Mrs Janine Marie Matthews 3,141,063 0.28%
    National Nominees Limited 2,856,026 0.25%
    Finclear Services Pty Ltd 2,729,106 0.24%
    Citicorp Nominees Pty Limited i 2,502,195 0.22%
    Tamit Nominees Pty Ltd 2,380,953 0.21%
    Mann Securities Pty Ltd 2,352,942 0.21%
    Lavya Pty Ltd 2,000,166 0.18%

    Profile

    since

    Note